Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX9930 Monotherapy vs C5 Inhibitor in PNH (REDEEM-1)
NCT05116774Phase 2Terminated
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Dec 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of vimircopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by BioCryst Pharmaceuticals, Inc.. Started Dec 2021; status: terminated.
02
Drugs
vimircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05116774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116774.